MAM
Carat to handle media duties of ABC Consultants
MUMBAI: Carat Media has won the media planning and buying duties of recruitment services brand ABC Consultants.
ABC will conduct an identity revival exercise and plans to execute a high voltage mass media campaign through Carat by investing close to Rs 100 million. The company aims to further strengthen its brand recall in the premier executive search and selection business.
Carat would be providing solutions for ABC Consultants through all its Aegis media partner agencies — Isobar, Posterscope, Carat Fresh and iProspect.
The campaign that is expected to break soon will be a combination of both ATL and BTL activities. The company is looking at print and online activities, along with direct B2B communication with clients, while the electronic medium, too, might be taken forward.
ABC Consultants CEO Shiv Agrawal said, “We are undergoing a major strategic renewal. In a growth-oriented scenario, we want to be the mind leader as far as quality manpower recruitment is concerned. We are delighted to have Carat Media as our partner in this endeavour of ours.”
Carat Media senior VP Vidhu Sagar added, “We feel privileged to be chosen for this exercise as ABC Consultants already has a significant draw in the marketplace as far as its brand equity is concerned. We would look to partner ABC Consultants through our integrated communication planning process and help them achieve their objectives.”
Brands
Sun Pharma to acquire Organon in $11.75 billion deal at $14 per share
Acquisition to create $12.4 billion pharma giant with global scale and biosimilars push
MUMBAI: Sun Pharmaceutical Industries Limited has signed a definitive agreement to acquire Organon & Co. in an all-cash deal valued at $11.75 billion, marking one of the largest cross-border pharma acquisitions by an Indian firm.
Under the terms of the agreement, Organon shareholders will receive $14.00 per share in cash, with Sun Pharma set to acquire 100 per cent of the company’s outstanding shares. The transaction, approved by the boards of both companies, is expected to close in early 2027, subject to regulatory approvals and shareholder consent.
The deal significantly expands Sun Pharma’s global footprint and strengthens its position across women’s health, biosimilars, and branded generics. The combined entity is projected to generate revenues of around $12.4 billion, placing it among the top 25 pharmaceutical companies globally.
Organon, which was spun off from Merck in 2021, brings a portfolio of over 70 products spanning women’s health and general medicines, with operations across more than 140 countries. Its established presence in key markets such as the US, Europe, and China complements Sun Pharma’s existing strengths and growth ambitions.
Sun Pharmaceutical Industries Limited executive chairman Dilip Shanghvi said, “This transaction represents a significant opportunity for Sun Pharma to build on its vision of reaching people and touching lives. Organon’s portfolio, capabilities and global reach are highly complementary to our own.”
Sun Pharmaceutical Industries Limited managing director Kirti Ganorkar added, “This transaction is a logical next step in strengthening Sun Pharma’s global business. Together, we will become a partner of choice for acquiring and launching new products.”
From Organon’s side, Organon & Co. executive chair Carrie Cox noted, “This all-cash transaction offers compelling and immediate value to Organon stockholders, while positioning the business for continued growth under Sun Pharma.”
Strategically, the acquisition gives Sun Pharma entry into the global biosimilars space as a top 10 player and strengthens its innovative medicines portfolio, which is expected to contribute around 27 per cent of combined revenues. The deal is also expected to nearly double EBITDA and cash flow, supporting long-term deleveraging and investment capacity.
Sun Pharma plans to fund the acquisition through a mix of internal accruals and committed financing from global banks, while maintaining focus on disciplined integration and operational continuity post-merger.
If completed as planned, the deal signals a clear shift in India’s pharmaceutical ambitions, from scale at home to leadership on the global stage, with Sun Pharma positioning itself as a more diversified and innovation-led healthcare powerhouse.
